Ability to generate 5,000 High-quality PPI Data per week
Using our SPID Platform with our next generation 384 High Throughput Pi-chip, we can generate high-quality antibody-antigen PPI big data as well as accurately measure antibody binding affinity. We continue to accelerate our data generation speed as we create PPI big data for an AI-based antibody drug discovery platform.
Antibody PPI Big Data
Antibody affinity measurement
Using SPID platform to analyze binding affinity and build binding affinity information matched with sequences
Antibody sequence variation
Generating new sequences by altering some protein sequences within the CDR regions where antibodies bind to antigens
Antibody library generation
Creating a large-scale sequence variant antibody library
*SPID Platform only requires small amounts of antibody due to high sensitivity
We are developing an AI-based antibody discovery platform, backed by our rapid antibody-antigen PPI data generation capabilities. This will revolutionize antibody drug discovery by enabling the de novo design of antibodies with optimal binding affinity to target antigens.
Our Antibody Drug Discovery Platform will leverage a generative AI model, developed together with Seoul National University using PROTEINA’s rapid antibody-antigen PPI data generation to revolutionize antibody drug discovery and development. By integrating the high-throughput capabilities of our SPID technology with our in-house generated datasets, the platform will enable the identification and optimization of therapeutic antibodies with unprecedented efficiency. We are currently producing 5,000 high-quality data points each week and using the generated big data to train the platform.
Our commitment to advancing antibody therapeutics ensures that our platform remains at the forefront of drug discovery innovation, driving the creation of next-generation treatments to improve patient outcomes and push the boundaries of medicine.
Antibody affinity maturation
Leverage PPI big data analytics to optimize antibody-based therapeutics
Antibody-Based Therapeutics
Monoclonal Antibodies, Bispecific Antibodies, ADC, etc.
